Skip to main content
Bildspel: 

Kerasal Nail™ approved in UAE

Moberg Pharma AB (OMX: MOB) today announced that its partner Leosons International has received approval for Kerasal Nail™ in UAE and will start launch preparations immediately.  Moberg Pharma signed a distribution agreement with Leosons International in October 2013 for sixteen markets in the MENA region.

"We signed the distribution agreement with Leosons just three months ago. The rapid approval confirms our strong belief that Leosons will do a great job distributing Kerasal Nail across the MENA region. The region includes more than 200 million people and represents a growing market opportunity. UAE is an important market and the expeditious approval of Kerasal Nail provides support for registrations in other countries in the region," said Peter Wolpert, President and CEO of Moberg Pharma AB.

About Moberg Pharma AB
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with its own sales organization in the US and sales through distributors in more than 40 countries. The company’s OTC portfolio includes the brands Kerasal®, Jointflex®, Kerasal Nail™Domeboro®, Vanquish®, Fergon®and Kaprolac®. Kerasal Nail™(Nalox™ in many markets) is the leading product for the treatment of nail disorders in the U.S and Nordic market. The portfolio is developed further through acquisitions and in-licensing of products as well as product development with focus on innovative drug delivery based on proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s share (OMX: MOB) is listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.se.

About Leosons International AB
Leosons International distributes pharmaceuticals, OTC products and Medical Equipment over 6 continents, with a focus on the MENA region (Middle East and North Africa). For further information, please visit: www.leosonsinternational.com